ES2159362T3 - Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica. - Google Patents

Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.

Info

Publication number
ES2159362T3
ES2159362T3 ES96934975T ES96934975T ES2159362T3 ES 2159362 T3 ES2159362 T3 ES 2159362T3 ES 96934975 T ES96934975 T ES 96934975T ES 96934975 T ES96934975 T ES 96934975T ES 2159362 T3 ES2159362 T3 ES 2159362T3
Authority
ES
Spain
Prior art keywords
trifluorometilfenil
iletil
tetrahydropiridine
naft
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96934975T
Other languages
English (en)
Inventor
Patrice Douillet
Jacqueline Fournier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512635A external-priority patent/FR2740343B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2159362T3 publication Critical patent/ES2159362T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE LA 1 - (2 - NAFT 2 - ILETIL) - 4 - (3 - TRIFLUOROMETILFENIL) - 1, 2, 3, 6 TETRAHIDROPIRIDINA O DE SUS SALES DE ADICION CON ACIDOS FARMACEUTICAMENTE ACEPTABLES PARA LA ELABORACION DE MEDICAMENTOS DESTINADOS AL TRATAMIENTO DE LA ESCLEROSIS LATERAL AMIOTROFICA (SLA).
ES96934975T 1995-10-26 1996-10-25 Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica. Expired - Lifetime ES2159362T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR9607336 1996-06-13

Publications (1)

Publication Number Publication Date
ES2159362T3 true ES2159362T3 (es) 2001-10-01

Family

ID=26232287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96934975T Expired - Lifetime ES2159362T3 (es) 1995-10-26 1996-10-25 Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.

Country Status (27)

Country Link
US (1) US6043251A (es)
EP (1) EP0866704B1 (es)
JP (1) JP3468526B2 (es)
KR (1) KR100472793B1 (es)
CN (1) CN1104241C (es)
AT (1) ATE200423T1 (es)
AU (1) AU719342B2 (es)
BR (1) BR9611124A (es)
CA (1) CA2235747C (es)
CY (1) CY2279B1 (es)
CZ (1) CZ293360B6 (es)
DE (1) DE69612510T2 (es)
DK (1) DK0866704T3 (es)
EE (1) EE04177B1 (es)
ES (1) ES2159362T3 (es)
GR (1) GR3036027T3 (es)
HU (1) HU222039B1 (es)
IL (1) IL124091A (es)
IS (1) IS1961B (es)
NO (1) NO316256B1 (es)
NZ (1) NZ320355A (es)
PT (1) PT866704E (es)
SI (1) SI0866704T1 (es)
SK (1) SK284099B6 (es)
TR (1) TR199800717T2 (es)
UA (1) UA57004C2 (es)
WO (1) WO1997015304A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
MXPA04005572A (es) * 2001-12-11 2004-12-06 Univ Virginia Uso de pramipexol para tratamiento de esclerosis lateral amiotrofica.
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US20080234338A1 (en) * 2005-08-15 2008-09-25 University Of Virginia Patent Foundation Neurorestoration With R(+) Pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2672731A1 (fr) * 1991-02-07 1992-08-14 France Telecom Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
NO316256B1 (no) 2004-01-05
CN1202826A (zh) 1998-12-23
HK1016904A1 (en) 1999-11-12
NO981856L (no) 1998-06-11
GR3036027T3 (en) 2001-09-28
WO1997015304A1 (fr) 1997-05-01
CZ293360B6 (cs) 2004-04-14
UA57004C2 (uk) 2003-06-16
KR19990067057A (ko) 1999-08-16
EP0866704A1 (fr) 1998-09-30
HUP9802945A3 (en) 1999-05-28
EE9800132A (et) 1998-10-15
NO981856D0 (no) 1998-04-24
CY2279B1 (en) 2003-07-04
IL124091A (en) 2003-10-31
EE04177B1 (et) 2003-12-15
CZ129698A3 (cs) 1998-07-15
SI0866704T1 (en) 2001-08-31
TR199800717T2 (xx) 1998-09-21
DE69612510D1 (de) 2001-05-17
KR100472793B1 (ko) 2005-06-16
ATE200423T1 (de) 2001-04-15
MX9803271A (es) 1998-09-30
JP3468526B2 (ja) 2003-11-17
AU719342B2 (en) 2000-05-04
EP0866704B1 (fr) 2001-04-11
DE69612510T2 (de) 2001-11-22
SK284099B6 (sk) 2004-09-08
HUP9802945A2 (hu) 1999-04-28
HU222039B1 (hu) 2003-03-28
CN1104241C (zh) 2003-04-02
IS4722A (is) 1998-04-21
BR9611124A (pt) 1999-05-11
CA2235747C (en) 2006-01-03
PT866704E (pt) 2001-07-31
AU7308496A (en) 1997-05-15
DK0866704T3 (da) 2001-07-16
IS1961B (is) 2004-11-15
JPH11515012A (ja) 1999-12-21
SK52698A3 (en) 1998-09-09
NZ320355A (en) 2000-03-27
CA2235747A1 (en) 1997-05-01
US6043251A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
ES2128761T3 (es) Formulacion de tirilazad con cosolvente para administracion parenteral.
DK0509317T3 (da) Lægemidler imod knoglesygdomme
NO306457B1 (no) 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
UY26320A1 (es) Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para la preparacion de medicamentos y formas de administracion que contienen esas sales. ley 17164
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
ES2176296T3 (es) Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.
MX171542B (es) Composiciones farmaceuticas que contienen deoxirribonucleosidos para cicatrizacion de heridas
EE04177B1 (et) 1-(2-naft-2-üületüül)-4-(3-trifluorometüülfenüül)-1,2,3,6-tetrahüdropüridiini kasutamine ravimite valmistamiseks amüotroofilise lateraalskleroosi raviks
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
SE9302218D0 (sv) New use
ATE87905T1 (de) Anticonvulsive agenzien.
NO941084D0 (no) Neuroleptiske 2-substituerte perhydro-1-H-pyrido[1,2-aÅpyraziner
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
RU98116380A (ru) Применение ингибиторов натрий-водородного обмена для получения лекарственного средства в целях лечения заболеваний, вызываемых простейшими
CO5021190A1 (es) Agentes terapeuticos
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
ES283591Y (es) Una tableta de dosificacion farmaceutica adecuada para administracion oral
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
ES2032572T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica para aplicacion topica sobre la piel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 866704

Country of ref document: ES